NewEdge Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

NewEdge Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150	Closed	-$1.42K	–	4013
2025 Q1	$1.42K	Hold	150	–	–	﹤0.01%	3573
2024 Q4	$1.85K	Buy	150 +50	+50%	+$706	﹤0.01%	3468
2024 Q3	$1.5K	Hold	100	–	–	﹤0.01%	3442
2024 Q2	$1.35K	Hold	100	–	–	﹤0.01%	3408
2024 Q1	$1.66K	Hold	100	–	–	﹤0.01%	3411
2023 Q4	$1.35K	Hold	100	–	–	﹤0.01%	3409
2023 Q3	$1.1K	Buy	100 +90	+900%	+$1.1K	﹤0.01%	3161
2023 Q2	$129	Hold	10	–	–	﹤0.01%	3410
2023 Q1	$120	Hold	10	–	–	﹤0.01%	3335
2022 Q4	$0	Buy	+10	New	+$146	﹤0.01%	4104

Other funds holding CNCR

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

NewEdge Advisors's CNCR Position: Q2 2025 in Review

NewEdge Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 150 shares — an estimated $1.42K sold.

NewEdge Advisors first reported a position in CNCR in Q4 2022 and held it in 10 quarters. The position peaked at $1.85K in Q4 2024. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.

NewEdge Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
NewEdge Advisors sold 150 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $1.42K.
NewEdge Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2022 and held it in 10 quarters.
NewEdge Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1.85K in Q4 2024.
1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.